AI-generated summary
The authors report an open label, single-arm study of 23 children aged 2 to 7 with autism spectrum disorder who received near-infrared light therapy to the head twice weekly for 10 weeks. They found a significant average reduction in CARS-2 symptom scores, with changes in EEG measures also reported. Without a control group, the findings cannot establish a causal effect.
- Participants
- 23
- Who or what was studied
- Children aged 2 to 7 previously diagnosed with autism spectrum disorder
- Wavelengths
- 850 nm
- Limits stated in the abstract
- The study is open label with a single arm and no control group, so the observed changes cannot be attributed to the treatment alone.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Small pilot studies have indicated that transcranial photobiomodulation (tPBM) may help alleviate symptoms of neurological conditions like depression, traumatic brain injury and Autism Spectrum Disorder (ASD).
Objective
To examine the effect of tPBM on the behavioral symptoms of ASD and brain electrophysiology in children aged 2-7.
Methods
We conducted an open label, one-arm study with 23 participants, aged 2-7, previously diagnosed with ASD. We delivered non-invasively to all participants pulses of near-infrared light (wavelength 850 nm, pulse 40 Hz) to cortical nodes of Default Mode Network, Broca and Wernicke areas, and occipital lobe of the brain, twice weekly for 10 weeks. The tPBM was delivered using an investigational medical device designed for this purpose. Changes in ASD symptoms were measured using pre- and post-intervention scores on the Childhood Autism Rating Scale (CARS-2, 2nd Edition). We collected electroencephalogram (EEG) data after each treatment session from all children who tolerated wearing the EEG cap to monitor changes in brain activity.
Results
The intervention resulted in a significant 7-point reduction in average CARS-2 scores (t = 10.23, p < .0001), along with decreased delta power and increased gamma and beta power in EEG readings. The increase in gamma power was statistically significant [t(14) = 2.30, p = 0.047]. Changes in EEG power were significantly correlated with the number of sessions (delta: r(192) = -0.18, p = .013; gamma: r(192) = .19, p = .007; beta: r(192) = .15, p = .04). Improvements in CARS-2 scores were negatively correlated with changes in delta and beta power (delta: r(15) = -.59, p = .020; beta: r(15) = -.54, p = .037). No moderate or severe side effects were reported.
Conclusion
This study supports the potential of tPBM as a safe and effective treatment for ASD, and it suggests that EEG measurements may serve as a useful biomarker for future research.
Trial Registration
https://clinicaltrials.gov/ct2/show/NCT04660552.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Autism, Electroencephalography, Photobiomodulation, Traumatic brain injury, Trial registration, Near-infrared, Brain injury. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.